Antifibrotic Therapy and Lung Cancer Risk in Patients With Idiopathic Pulmonary Fibrosis: A Large Retrospective Propensity-Weighted Cohort Study

This study investigated whether antifibrotic therapy is associated with a reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis (IPF). Using a large retrospective cohort from the Mayo Clinic spanning 2005 to 2022, the authors compared 3,313 IPF patients who did and did not receive continuous antifibrotic treatment for at least six months. After balancing the groups using propensity score weighting, they found that the incidence of lung cancer was significantly lower in patients treated with antifibrotics, 0.34 vs 1.25 cases per 100 person-years. Additionally, antifibrotic use was independently associated with a reduced risk of lung cancer (subdistribution hazard ratio 0.36, p = 0.02). Traditional risk factors, such as smoking history and higher forced vital capacity, were linked to a greater cancer risk. 
 
This article is important for the cardiothoracic surgery community because lung cancer commonly complicates IPF and often limits surgical options due to poor pulmonary reserve and high perioperative risk. Understanding that antifibrotic therapy may lower lung cancer risk could influence long-term management strategies, the timing of surgical intervention, and surveillance protocols in patients with fibrotic lung disease, making it highly relevant to CTSNet’s global audience.